{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:25:24Z","timestamp":1768731924206,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40265-021-01518-w","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T13:05:13Z","timestamp":1618837513000},"page":"709-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Indacaterol\/Glycopyrronium\/Mometasone: A Review in Asthma"],"prefix":"10.1007","volume":"81","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"1","key":"1518_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41533-020-0182-2","volume":"30","author":"K Larsson","year":"2020","unstructured":"Larsson K, Kankaanranta H, Janson C, et al. Bringing asthma care into the twenty-first century. NPJ Prim Care Respir Med. 2020;30(1):25.","journal-title":"NPJ Prim Care Respir Med."},{"key":"1518_CR2","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. https:\/\/ginasthma.org. Accessed 25 Mar 2021."},{"issue":"11","key":"1518_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/17476348.2019.1657408","volume":"13","author":"M Cazzola","year":"2019","unstructured":"Cazzola M, Puxeddu E, Matera MG, et al. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019;13(11):1079\u201385.","journal-title":"Expert Rev Respir Med."},{"key":"1518_CR4","unstructured":"European Medicines Agency. Enerzair Breezhaler: EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu. Accessed 25 Mar 2021."},{"issue":"1","key":"1518_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12931-020-01501-1","volume":"21","author":"D Miller","year":"2020","unstructured":"Miller D, Vaidya S, Jauernig J, et al. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. Respir Res. 2020;21(1):248.","journal-title":"Respir Res."},{"key":"1518_CR6","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.pupt.2020.101919","volume":"62","author":"R Buhl","year":"2020","unstructured":"Buhl R, Tanase AM, Hosoe M, et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler\u00ae or Twisthaler\u00ae in patients with asthma. Pulm Pharmacol Ther. 2020;62:101919.","journal-title":"Pulm Pharmacol Ther."},{"key":"1518_CR7","doi-asserted-by":"crossref","unstructured":"Rogliani P, Ritondo BL, Nikolaev I, et al. IND\/GLY\/MF: synergism in medium and small human hyperresponsive airways [abstract no. 2900]. Eur Respir J. 2020;56(Suppl. 64).","DOI":"10.1183\/13993003.congress-2020.2900"},{"key":"1518_CR8","doi-asserted-by":"publisher","first-page":"101964","DOI":"10.1016\/j.pupt.2020.101964","volume":"64","author":"S Vaidya","year":"2020","unstructured":"Vaidya S, Jauernig J, Ethell B, et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Pulm Pharmacol Ther. 2020;64:101964.","journal-title":"Pulm Pharmacol Ther."},{"key":"1518_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102019","author":"S Vaidya","year":"2021","unstructured":"Vaidya S, Ziegler D, Tanase A-M, et al. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. Pulm Pharmacol Ther. 2021. https:\/\/doi.org\/10.1016\/j.pupt.2021.102019.","journal-title":"Pulm Pharmacol Ther."},{"issue":"1","key":"1518_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12890-020-01382-6","volume":"21","author":"S Inoue","year":"2021","unstructured":"Inoue S, Vaidya S, Tillmann HC, et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC Pulm Med. 2021;21(1):18.","journal-title":"BMC Pulm Med."},{"issue":"10","key":"1518_CR11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000\u201312.","journal-title":"Lancet Respir Med."},{"issue":"106021","key":"1518_CR12","first-page":"1","volume":"170","author":"C Gessner","year":"2020","unstructured":"Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol\/glycopyrronium\/mometasone furoate once-daily versus salmeterol\/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170(106021):1\u201310.","journal-title":"Respir Med."},{"issue":"9","key":"1518_CR13","first-page":"A1277","volume":"199","author":"J Beier","year":"2019","unstructured":"Beier J, Watz H, Scholz V, et al. The efficacy of the combination indacaterol\/glycopyrronium\/mometasone furoate is independent of time of dosing in patients with asthma [abstract no. P665 plus poster]. Am J Respir Crit Care Med. 2019;199(9):A1277.","journal-title":"Am J Respir Crit Care Med."},{"issue":"87","key":"1518_CR14","first-page":"1","volume":"21","author":"H Watz","year":"2020","unstructured":"Watz H, Hohlfeld JM, Singh D, et al. Letter to the editor: indacaterol\/glycopyrronium\/mometasone furoate compared with salmeterol\/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. Respir Res. 2020;21(87):1\u20135.","journal-title":"Respir Res."},{"key":"1518_CR15","doi-asserted-by":"crossref","unstructured":"Chapman KR, Watz H, Beier J, et al. Lung function normalization with indacaterol\/glycopyrronium\/mometasone furoate in patients with asthma [abstract no. PA2539 plus poster]. Eur Respir J. 2019;54(Suppl. 63).","DOI":"10.1183\/13993003.congress-2019.PA2539"},{"key":"1518_CR16","doi-asserted-by":"crossref","unstructured":"Chapman KR, Watz H, Beier J, et al. Indacaterol\/glycopyrronium\/mometasone furoate combination consistently shows lung function benefits in patients with asthma [abstract no. PA3720 plus poster]. Eur Respir J. 2019;54(Suppl. 63).","DOI":"10.1183\/13993003.congress-2019.PA3720"},{"key":"1518_CR17","first-page":"A3012","volume":"201","author":"H Sagara","year":"2020","unstructured":"Sagara H, D\u2019Andrea P, Tanase A, et al. Once-daily indacaterol acetate, glycopyrronium bromide, and mometasone furoate as a fixed-dose combination in Japanese patients with inadequately controlled asthma: a multicenter, 52-week safety study [abstract no. P371]. Am J Respir Crit Care Med. 2020;201:A3012.","journal-title":"Am J Respir Crit Care Med."},{"issue":"1","key":"1518_CR18","doi-asserted-by":"publisher","first-page":"e000856","DOI":"10.1136\/bmjresp-2020-000856","volume":"8","author":"H Sagara","year":"2021","unstructured":"Sagara H, Barbier N, Ishii T, et al. Efficacy of one time per day, single-inhaler indacaterol\/glycopyrronium\/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population. BMJ Open Respir Res. 2021;8(1):e000856.","journal-title":"BMJ Open Respir Res."},{"key":"1518_CR19","unstructured":"Chapman KR, Kostikas K, Kerstjens HAM, et al. Reduction in asthma exacerbations with indacaterol\/glycopyrronium\/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study [abstract no. PA2281 plus poster]. In: European Respiratory Society International Congress. 2020."},{"key":"1518_CR20","doi-asserted-by":"crossref","unstructured":"Gessner C, Kornmann O, Maspero J, et al. Lower ICS dose effect on symptoms and rescue medication use of indacaterol\/glycopyrronium\/mometasone (IND\/GLY\/MF) medium-dose vs salmeterol\/fluticasone (SAL\/FLU) high-dose plus tiotropium (TIO): ARGON study [abstract no. 2634 plus poster]. In: European Respiratory Society International Congress. 2020.","DOI":"10.1183\/13993003.congress-2020.2634"},{"key":"1518_CR21","doi-asserted-by":"publisher","first-page":"106311","DOI":"10.1016\/j.rmed.2021.106311","volume":"180","author":"E Scosyrev","year":"2021","unstructured":"Scosyrev E, van Zyl-Smit R, Kerstjens H, et al. Cardiovascular safety of mometasone\/indacaterol and mometasone\/indacaterol\/glycopyrronium once-daily fixed-dose combinations in asthma. Respir Med. 2021;180:106311.","journal-title":"Respir Med."},{"issue":"10","key":"1518_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S2213-2600(20)30303-9","volume":"8","author":"JC Virchow","year":"2020","unstructured":"Virchow JC. Assessing the benefits of triple versus dual fixed-dose combinations for the treatment of severe asthma. Lancet Respir Med. 2020;8(10):937\u20139.","journal-title":"Lancet Respir Med."},{"key":"1518_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01021-w","author":"M Molimard","year":"2021","unstructured":"Molimard M, Kottakis I, Jauernig J, et al. Performance characteristics of Breezhaler\u00ae and Aerolizer\u00ae in the real-world setting. Clin Drug Investig. 2021. https:\/\/doi.org\/10.1007\/s40261-021-01021-w.","journal-title":"Clin Drug Investig."},{"key":"1518_CR24","unstructured":"European Medicines Agency. Enerzair Breezhaler: assessment report. 2020. https:\/\/www.ema.europa.eu. Accessed 25 Mar 2021."},{"key":"1518_CR25","unstructured":"European Medicines Agency. Human medicines highlights 2020. 2020. https:\/\/www.ema.europa.eu. Accessed 25 Mar 2021."},{"key":"1518_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","volume":"3","author":"C Nunes","year":"2017","unstructured":"Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.","journal-title":"Asthma Res Pract."},{"issue":"Suppl. 2","key":"1518_CR27","doi-asserted-by":"publisher","first-page":"S719","DOI":"10.1016\/j.jval.2020.08.1895","volume":"23","author":"PP Mangia","year":"2020","unstructured":"Mangia PP, Pradelli L, Gallo O, et al. Cost-utility analysis of fixed dose combination (FDC) of indacaterol acetate (IND) glycopyrronium bromide (GLY) and mometasone furoate (MF) as a maintenance treatment in adult asthma patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year [abstract no. PRS15]. Value Health. 2020;23(Suppl. 2):S719.","journal-title":"Value Health."},{"issue":"Suppl. 2","key":"1518_CR28","doi-asserted-by":"publisher","first-page":"S723","DOI":"10.1016\/j.jval.2020.08.1918","volume":"23","author":"S Gupta","year":"2020","unstructured":"Gupta S, Muthukumar M, Marvel J, et al. Cost-effectiveness of once-daily single-inhaler indacaterol acetate\/glycopyrronium bromide\/mometasone furoate in patients with uncontrolled moderate-to-severe asthma [abstract no. PRS38]. Value Health. 2020;23(Suppl. 2):S723.","journal-title":"Value Health."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01518-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T10:43:55Z","timestamp":1620297835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01518-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01518-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"1 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}